Noninvasive Assessment of Pulmonary Fluid Levels by Remote Dielectric Sensing Technology to Improve Cardiac InsUfficieney During Ischemia-Reperfusion and Clinical Outcomes in MyocArdiaL Infarction

Launched by SHANGHAI 10TH PEOPLE'S HOSPITAL · Oct 31, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to help patients who have experienced a heart attack and are also having trouble with heart function. Researchers want to see if using a special device called ReDS can provide better information about fluid levels in the lungs compared to standard care. This could help doctors make better decisions and improve patient outcomes after a heart attack.

To be eligible for this trial, participants need to be at least 18 years old and currently hospitalized for a heart attack, along with showing signs of heart failure, which might include swelling or shortness of breath. However, certain patients cannot participate, such as those with specific lung diseases or other serious health issues. If you qualify and decide to join, you can expect to receive close monitoring and care throughout the study, which aims to find ways to improve recovery after a heart attack.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients were required to be aged ≥ 18 years and to be hospitalized for a primary diagnosis of AMI,
• • 2. AMI patients accompanied by cardiac insufficiency following coronary revascularization, which is characterized by the symptoms and signs of fluid overload, regardless of left ventricular ejection fraction (LVEF), and have an N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration of ≥ 400 pg/L or a BNP concentration of ≥ 100 pg/L.
• Exclusion Criteria:
• • 1. Patient's physical characteristics that prevented the use of the ReDS system (height of \<155 or \>190 cm; body mass index of \<22 or \>39 kg/m2)
• • 2. Patients with chronic obstructive pulmonary disease or other lung diseases that might confound ReDS values
• • 3. Patients with a left ventricular assist device or undergoing cardiac transplantation;
• • 4. Patients with congenital heart malformations or intrathoracic mass that would affect right lung anatomy;
• • 5. Patients with end-stage renal disease on hemodialysis;
• • 6. Patients whose life expectancy less than 12 months due to noncardiac comorbidities
• • 7. Patients who participate in another randomized studies.